高危型人乳头瘤病毒感染对食管癌不良预后的研究
|
摘要
研究背景：
食管癌是世界范围内常见的,且具有明显地区聚集性的恶性肿瘤。在我国,食管癌预后较差,其死亡率一直居高不下,现位居所有肿瘤死亡原因的第四位,同样具有地域分布特征。广东汕头地区是我国唯一沿海食管癌高发区。我们前期研究表明该地区食管癌患者癌组织中人乳头瘤病毒(Human papillomavirus, HPV)感染率在50-80%之间,并且以高危型HPV感染为主,但HPV感染对食管癌的致病机理和预后状况尚不清楚。
端粒和端粒酶是染色体末端一种维持染色体完整和稳定的特殊结构,能防止染色体DNA降解、末端融合缺失和非正常重组。研究表明,端粒长度的进行性缩短和端粒酶的激活在肿瘤细胞的恶性转化和进展中起着重要作用。而端粒长度和端粒酶的表达均与端粒酶相关基因或亚端粒的DNA甲基化调控有关。因此,从端粒酶的表观遗传学修饰的角度探讨HPV感染与食管癌的相关性有助于食管癌病因学和食管癌患者预后的研究。
研究目的与假说：
目的：从端粒酶相关基因或亚端粒的DNA甲基化的角度分析HPV和端粒长度的相关性,以及对食管癌预后的影响,以期能为食管癌的病因学研究和预后分析提供一定的理论依据。
假说：食管癌细胞中高危型HPV持续感染→HPV DNA断裂,E6/7癌基因整合入宿主基因组DNA的“脆性部位”→HPVE6/7癌蛋白稳定持续的表达→端粒酶相关基因(hTERT和TRF2)或亚端粒的DNA甲基化改变→食管癌中端粒长度的变化→增加癌细胞的恶性转化和永生化→影响食管癌患者预后。
研究方法：
通过构建分别含有HPV-16,-18和-58型E6/7和E2基因片段的质粒DNA,建立稳定且灵敏的绝对实时定量PCR技术(quantitative real time PCR, qPCR),对70例食管癌患者中的癌组织及其配对的癌旁正常食管组织,以及60例正常人的食管粘膜组织中的高危型HPV-16,-18和-58型感染的病毒含量(E6/7基因拷贝数)和整合量(E2基因和E6/7基因拷贝数的比值)进行定量检测；
采用免疫组化(immunohistochemistry, IHC)技术检测食管癌中HPV16E6蛋白的表达情况；
以HEK293细胞DNA为标准品,采用实时定量PCR技术建立端粒长度的定量检测法方法,以检测食管癌和正常食管组织中的端粒长度；
采用甲基化特异性PCR (methylation-specific PCR, MSP)技术检测食管癌中端粒酶相关基因人端粒酶催化亚单位(human reverse-transcriptase telomerase,端粒重复序列结合因子(Telomeric repeat-binding factor2, TRF2)和亚端粒DNA甲基化。
采用SPSS16.0软件统计分析高危型HPV感染,端粒长度与DNA甲基化水平的三者之间相关性,以及对食管癌预后的影响。
研究结果：
(1)对构建的系列浓度HPV E6/7和E2基因标准品——含有HPV-16E6/7、HPV-16E2, HPV-18E6/7、HPV-18E2、HPV-58E6/7和HPV58E2基因片段质粒DNA,进行定量PCR扩增,其特异性较好。六种基因标准曲线的R2分别为0.9945、0.991、0.995、0.9976、0.9879和0.999,经相关性检验发现六个标准曲线均具有显著的相关性(P<0.05)。同时,E6/7和E2基因分别在三种型别HPV的扩增效率相一致。
(2)食管癌组织中HPV-16,-18和-58病毒含量变异均较大,但三者之间无显著性差别。在食管癌组织中,三种型别HPV合并感染率和感染量均显著性高于正常食管组织(50.00%vs.33.33%, P=0.045;2.55±3.19vs.0.55±0.57copies/cell,P=0.021)。同时,HPV DNA的混合状态或整合状态在食管癌和正常食管中均较高(91.43%vs.85.00%),但在食管癌中的整合状态比正常食管组织中显著性增高(F=17.832,P=0.001)。高危型HPV DNA的整合量与肿瘤分级呈正相关(r=3.753,P=0.033),但与年龄、性别、吸烟、饮酒、家族史和淋巴结转移无关。HPV病毒含量与临床资料均无显著相关性。
(3)免疫组化检测发现HPV16主要定位于食管癌细胞浆,HPV16蛋白在食管癌组织中的阳性率为59.26%,并随着肿瘤分级的增加而增加(r=0.301,P=0.027)。
(4)从正常食管,到食管癌旁正常组织再到食管癌中,端粒长度依次缩短[4.77(4.28-5.33,),4.37(3.89-5.09)和4.27(3.79-4.57)kb](P趋势性检验<0.01)。
(5)HPV或高危型HPV仅能延长食管癌组织中的端粒长度,而不影响正常食管和癌旁正常组织中的端粒长度。同时在食管癌组织中,端粒长度分别和高危型HPV基因的感染量和整合量呈正相关(r=0.410, P=0.037; r=0.492, P=0.01)。
(6)食管癌组织中的端粒长度和癌/癌旁端粒长度比值分别在高危型HPV感染患者、食管癌细胞中HPV含量大于1的患者和HPV整合状态的患者中较长/大。同时,癌/癌旁端粒长度比值在吸烟患者、肿瘤分级为Ⅱ和Ⅲ的患者以及5年内死亡的患者中较大。
(7)甲基化特异性PCR检测发现,食管癌中hTERT,7q,9q和XqYq均呈高甲基化状态,而TRF2、17q、18q和21q则呈低甲基化状态。7q基因甲基化水平分别与9q、18q呈正相关。而TRF2基因甲基化水平分别与hTERT、21q呈负相关。
(8)相对与HPV阴性的食管癌患者,高危型HPV感染的患者中hTERT、18q和21q基因的甲基化水平较高,而TRF2较低。高危型HPV的整合量与hTERT甲基化水平呈正相关,与TRF2呈正相关。HPV病毒量和hTET、TRF2、7q、9q、17q、18q、21q、和XqYq基因甲基化水平无相关性。
(9)相对于食管癌组织中端粒相对长度<0.7的患者,端粒相对长度≥0.7的患者中,hTERT和21q基因的甲基化水平增高,而TRF2则降低。食管癌组织中端粒长度分别与hTERT (r=0.318, P=0.007)和21q (r=0.297, P=0.013)基因甲基化水平呈正相关。
(10)采用Kaplan-Meier分析和单因素Cox回归模型分析显示：肿瘤分级为Ⅲ级的食管癌患者,高危型HPV感染的患者以及癌/癌旁端粒长度比值≥0.8的患者预后较差,其生存的相对危险比(95%置信区间)值分别是对照组的3.13(1.26-7.50)、1.93(1.04-3.57)和2.30(1.19-4.46)。而食管癌患者的预后与年龄、性别、吸烟、家族史、淋巴结转移和HPV感染无关。采用多因素Cox回归模型分析显示：只有癌/癌旁端粒长度比值和高危型HPV感染分别是食管癌预后的独立指标,癌/癌旁端粒长度比值越大或高危型HPV感染的食管癌预后越差。
研究小结：
(1)采用实时定量PCR技术,我们构建了稳定且灵敏的HPV16,-18和-58型病毒绝对含量和整合量,以及相对端粒长度的检测方法；
(2)食管癌患者中高危型HPV感染的拷贝数较低,但HPV DNA的高整合率可维持其蛋白的高表达状态；
(3)端粒长度在食管癌变过程中进行性缩短,高危型HPV感染可逆转食管癌中端粒的缩短,使端粒长度维持在一定的长度；
(4)高危型HPV感染维持端粒长度的过程与hTERT、TRF2和亚端粒21q的DNA甲基化水平有关；
(5)高危型HPV感染、食管癌/癌旁端粒长度的比值分别是影响食管癌患者不良预后的独立危险因素。
研究结论：
食管癌患者肿瘤细胞中高危型HPV DNA的高感染率和整合率使其E6/7癌蛋白持续性高表达,进而可能通过端粒酶相关基因hTERT和TRF2的DNA甲基化水平的改变,影响了端粒酶活性,逆转食管癌中端粒的进行性缩短,增加细胞的恶性转化和永生化,与食管癌患者的不良预后密切相关。
Background:
Esophageal squamous cell carcinoma (ESCC) is a common malignancy with high mortality and ranks as the fourth most frequent cause of cancer death in China as well as in worldwide. The Shantou of eastern Guangdong province, in southern China, is only one of coastal area with the high incidence of esophageal carcinoma (EC). The presence of (Human papillomavirus, HPV), mainly for high risk of HPV (HR-HPV), in cases of ESCC has been reported repeatedly about50-80%from Shantou, China, and other regions with a high incidence of esophageal carcinoma (EC). Thus, the role of high-risk HPV types in the carcinogenesis and prognosis of ESCC remains uncertain.
Telomeres and Telomerase, as the special structure at the ends of chromosomes, could maintain the stability, and prevent the degradation, abnormal terminal fusion or recombinant of chromosomal DNA. Telomere shortening and activation, which related with DNA methylation of telomere and subtelomere, is crucial in carcinogenesis and tumor progression. It's helpful for etiology study of EC to research the relationship between HPV infection and epigenetic mechanism.
Aim and Hypothesis:
Here, we fully explored the association among HR-HPV infection load and integration, telomere length (TL) and DNA methylation of telomerase related gene and submelomere, as well as their significance in the prognosis of ESCC, so as to provide some supplements to the etiology study of EC.
Our hypothesis as following:HR-HPV sustain infection in ESCC→HPV DNA breakage and its E6/7oncogene integration at the "fragile site" of the host chromosomes→The sustain and continuous expression of HPVE6/7oncoprotein→The changes of telomerase related gene (hTERT and TRF2) and subtelomere DNA methylation level→Effect of telomere length→Promotion of the malignant transformation and immortalization→Affect the prognosis of ESCC patients.
Method:
We established a stable and sensitive methodology of real time PCR to assess the prevalence, viral load and physical status of HR-HPV-16,-18and-58, infection the3most common HR-HPVs, as well as telomere length (LT) in patients with70cases of ESCC tumor (T) tissues and paired of paired nontumor (NT) tissues and50cases of normal esophagus (NE). DNA methylation and HPV-16protein expression were carried out by methylation-specific PCR (MSP) and using immunohistochemistry (IHC) assay, respectively. The prognostic value of TL and DNA methylation in ESCC was analyzed using SPSS16.0soft ware (SPSS Inc., Chicago, IL).
Results:
(1) All typical amplification plots involved HPV-16,-18and-58types for E2and E6/7plasmid DNA (change in the fluorescent signal versus cycle number). Six of standard curve showed a dynamic linear range for quantification across copy number over the entire range of dilution concentrations on bivariate correlation analysis (P<0.05).
(2) Widespread, but no difference of HR-HPV-16,-18and-58vial loads were found. The combined infection rates (50.00%vs.33.33%, P=0.045) and viral load (2.55±3.19vs.0.55±0.57copies/cell, P=0.029) for all HR-HPVs in ESCC patients was significantly higher than that of their corresponding controls. HPV DNA integration and mixed forms were more frequently observed in ESCC patients and in controls (91.43%vs.85.00%). The frequency of HR-HPV integration was higher than that for ESCC controls (F=17.832, P=0.001). The integration level was associated with pathological grade of ESCC (r=3.753, P=0.033). However, no significant associations were found between HPV physical status and patient age or lymph-node metastasis. HPV viral loads were not associated with ESCC patient age, lymph-node metastasis or cancer grade.
(3) IHC assay indicated that HPV-16protein expression, located mainly in the cytoplasm of cancer cells, was detected in59.26%of ESCC tissues and was positively correlated with pathological grade of cancer (r=0.301, P=0.027) in ESCC patients.
(4) TL decreased from normal esophagus mucosa, adjacent NT tissue to T tissue [4.77(4.28-5.33),4.37(3.89-5.09) and4.27(3.79-4.57) kb].
(5) T-TL was longer in ESCC samples positive for HPV (represented as low-risk HPV and HR-HPV) or HR-HPV. T-TL was positively correlated with viral load (r=0.410, P=0.037) and integration (r=0.492, P=0.01).
(6) Relatively long T-TL and high T/NT-TL ratio were frequently found with high viral load and integrated status. T/NT-TL was higher in ESCC patients with smoking, HPV infection or tumor grade III. T/NT-TL ratio was higher for surviving than non-surviving patients.
(7) Using MSP method, we found a hyper-methylation ratio (≥60%) for hTERT,7q,9q and XqYq but a hypo-methylation ratio (<40%) for TRF2,17q, and21q. we also found the concordant methylation level of7q and9q (r=0.304, P=0.011) and18q (r=0.311, P=0.009). The methylation level of hTERT and21q was negatively correlated with that of TRF2(r=-0.281, P=0.025, and r=-0.251, P=0.036, respectively).
(8) HR-HPV positivity increased the levels of hTERT,18q and21q methylation and decreased that of TFR2methylation. Furthermore, HR-HPV integration was positively correlated with hTERT methylation (r=0.413, P=0.036) and positively with TRF2methylation (r=0.453, P=0.02). However, HR-HPV viral load did not affect the ratio of hTERT, TRF2and subtelomere DNA methylation.
(9) High hTERT and21q methylation was more prevalent with long than short T-TL and was positively correlated with T-TL.
(10) Kaplan-Meier analysis and Univariate Cox regression analysis revealed significantly worse outcomes for patients with cancer grade Ⅲ (PHR=0.013), HR-HPV infection (PHR=0.037) and high T/NT-TL ratio (PHR=0.014). Multivariate survival analysis with a Cox proportional-hazards model revealed HR-HPV infection and high T/NT-TL ratio as the poor prognostic factors of survival, independent of age, gender, smoking, alcohol drinking, lymph node metastasis and cancer grade.
Summary:
(1) We established a stable and sensitive methodology of real time PCR to assess the viral load and physical status of HR-HPV-16,-18and-58DNA, as well as the relative telomere length.
(2) A relatively low HR-HPV copy number infection in ESCC is unlikely to play an essential a role in the carcinogenesis of ESCC. However, the mainly presentation of the physical status could sustain the high expression of the HR-HPV types in ESCC, which strongly suggests a possible role of oncogenic HPV infection in carcinogenesis of ESCC.
(3) TL gradually decreased in the process of esophageal carcinogenesis. HR-HPV infection could reverse the shortening of LT and maintain the TL in a critical length.
(4) DNA methylation levels of hTERT, TRF2and21q were participated in the maintenance of LT by HR-HPV infection.
(5) HR-HPV infection and high T/NT-TL ratio was the dependent of prognostic factors for the poor survival of ESCC.
Conclusion:
HR-HPV integration and expression related to telomere elongation and DNA methylation of hTERT and TRF2, may be a potential biomarker of prognosis in ESCC.
食管癌是世界范围内常见的,且具有明显地区聚集性的恶性肿瘤。在我国,食管癌预后较差,其死亡率一直居高不下,现位居所有肿瘤死亡原因的第四位,同样具有地域分布特征。广东汕头地区是我国唯一沿海食管癌高发区。我们前期研究表明该地区食管癌患者癌组织中人乳头瘤病毒(Human papillomavirus, HPV)感染率在50-80%之间,并且以高危型HPV感染为主,但HPV感染对食管癌的致病机理和预后状况尚不清楚。
端粒和端粒酶是染色体末端一种维持染色体完整和稳定的特殊结构,能防止染色体DNA降解、末端融合缺失和非正常重组。研究表明,端粒长度的进行性缩短和端粒酶的激活在肿瘤细胞的恶性转化和进展中起着重要作用。而端粒长度和端粒酶的表达均与端粒酶相关基因或亚端粒的DNA甲基化调控有关。因此,从端粒酶的表观遗传学修饰的角度探讨HPV感染与食管癌的相关性有助于食管癌病因学和食管癌患者预后的研究。
研究目的与假说：
目的：从端粒酶相关基因或亚端粒的DNA甲基化的角度分析HPV和端粒长度的相关性,以及对食管癌预后的影响,以期能为食管癌的病因学研究和预后分析提供一定的理论依据。
假说：食管癌细胞中高危型HPV持续感染→HPV DNA断裂,E6/7癌基因整合入宿主基因组DNA的“脆性部位”→HPVE6/7癌蛋白稳定持续的表达→端粒酶相关基因(hTERT和TRF2)或亚端粒的DNA甲基化改变→食管癌中端粒长度的变化→增加癌细胞的恶性转化和永生化→影响食管癌患者预后。
研究方法：
通过构建分别含有HPV-16,-18和-58型E6/7和E2基因片段的质粒DNA,建立稳定且灵敏的绝对实时定量PCR技术(quantitative real time PCR, qPCR),对70例食管癌患者中的癌组织及其配对的癌旁正常食管组织,以及60例正常人的食管粘膜组织中的高危型HPV-16,-18和-58型感染的病毒含量(E6/7基因拷贝数)和整合量(E2基因和E6/7基因拷贝数的比值)进行定量检测；
采用免疫组化(immunohistochemistry, IHC)技术检测食管癌中HPV16E6蛋白的表达情况；
以HEK293细胞DNA为标准品,采用实时定量PCR技术建立端粒长度的定量检测法方法,以检测食管癌和正常食管组织中的端粒长度；
采用甲基化特异性PCR (methylation-specific PCR, MSP)技术检测食管癌中端粒酶相关基因人端粒酶催化亚单位(human reverse-transcriptase telomerase,端粒重复序列结合因子(Telomeric repeat-binding factor2, TRF2)和亚端粒DNA甲基化。
采用SPSS16.0软件统计分析高危型HPV感染,端粒长度与DNA甲基化水平的三者之间相关性,以及对食管癌预后的影响。
研究结果：
(1)对构建的系列浓度HPV E6/7和E2基因标准品——含有HPV-16E6/7、HPV-16E2, HPV-18E6/7、HPV-18E2、HPV-58E6/7和HPV58E2基因片段质粒DNA,进行定量PCR扩增,其特异性较好。六种基因标准曲线的R2分别为0.9945、0.991、0.995、0.9976、0.9879和0.999,经相关性检验发现六个标准曲线均具有显著的相关性(P<0.05)。同时,E6/7和E2基因分别在三种型别HPV的扩增效率相一致。
(2)食管癌组织中HPV-16,-18和-58病毒含量变异均较大,但三者之间无显著性差别。在食管癌组织中,三种型别HPV合并感染率和感染量均显著性高于正常食管组织(50.00%vs.33.33%, P=0.045;2.55±3.19vs.0.55±0.57copies/cell,P=0.021)。同时,HPV DNA的混合状态或整合状态在食管癌和正常食管中均较高(91.43%vs.85.00%),但在食管癌中的整合状态比正常食管组织中显著性增高(F=17.832,P=0.001)。高危型HPV DNA的整合量与肿瘤分级呈正相关(r=3.753,P=0.033),但与年龄、性别、吸烟、饮酒、家族史和淋巴结转移无关。HPV病毒含量与临床资料均无显著相关性。
(3)免疫组化检测发现HPV16主要定位于食管癌细胞浆,HPV16蛋白在食管癌组织中的阳性率为59.26%,并随着肿瘤分级的增加而增加(r=0.301,P=0.027)。
(4)从正常食管,到食管癌旁正常组织再到食管癌中,端粒长度依次缩短[4.77(4.28-5.33,),4.37(3.89-5.09)和4.27(3.79-4.57)kb](P趋势性检验<0.01)。
(5)HPV或高危型HPV仅能延长食管癌组织中的端粒长度,而不影响正常食管和癌旁正常组织中的端粒长度。同时在食管癌组织中,端粒长度分别和高危型HPV基因的感染量和整合量呈正相关(r=0.410, P=0.037; r=0.492, P=0.01)。
(6)食管癌组织中的端粒长度和癌/癌旁端粒长度比值分别在高危型HPV感染患者、食管癌细胞中HPV含量大于1的患者和HPV整合状态的患者中较长/大。同时,癌/癌旁端粒长度比值在吸烟患者、肿瘤分级为Ⅱ和Ⅲ的患者以及5年内死亡的患者中较大。
(7)甲基化特异性PCR检测发现,食管癌中hTERT,7q,9q和XqYq均呈高甲基化状态,而TRF2、17q、18q和21q则呈低甲基化状态。7q基因甲基化水平分别与9q、18q呈正相关。而TRF2基因甲基化水平分别与hTERT、21q呈负相关。
(8)相对与HPV阴性的食管癌患者,高危型HPV感染的患者中hTERT、18q和21q基因的甲基化水平较高,而TRF2较低。高危型HPV的整合量与hTERT甲基化水平呈正相关,与TRF2呈正相关。HPV病毒量和hTET、TRF2、7q、9q、17q、18q、21q、和XqYq基因甲基化水平无相关性。
(9)相对于食管癌组织中端粒相对长度<0.7的患者,端粒相对长度≥0.7的患者中,hTERT和21q基因的甲基化水平增高,而TRF2则降低。食管癌组织中端粒长度分别与hTERT (r=0.318, P=0.007)和21q (r=0.297, P=0.013)基因甲基化水平呈正相关。
(10)采用Kaplan-Meier分析和单因素Cox回归模型分析显示：肿瘤分级为Ⅲ级的食管癌患者,高危型HPV感染的患者以及癌/癌旁端粒长度比值≥0.8的患者预后较差,其生存的相对危险比(95%置信区间)值分别是对照组的3.13(1.26-7.50)、1.93(1.04-3.57)和2.30(1.19-4.46)。而食管癌患者的预后与年龄、性别、吸烟、家族史、淋巴结转移和HPV感染无关。采用多因素Cox回归模型分析显示：只有癌/癌旁端粒长度比值和高危型HPV感染分别是食管癌预后的独立指标,癌/癌旁端粒长度比值越大或高危型HPV感染的食管癌预后越差。
研究小结：
(1)采用实时定量PCR技术,我们构建了稳定且灵敏的HPV16,-18和-58型病毒绝对含量和整合量,以及相对端粒长度的检测方法；
(2)食管癌患者中高危型HPV感染的拷贝数较低,但HPV DNA的高整合率可维持其蛋白的高表达状态；
(3)端粒长度在食管癌变过程中进行性缩短,高危型HPV感染可逆转食管癌中端粒的缩短,使端粒长度维持在一定的长度；
(4)高危型HPV感染维持端粒长度的过程与hTERT、TRF2和亚端粒21q的DNA甲基化水平有关；
(5)高危型HPV感染、食管癌/癌旁端粒长度的比值分别是影响食管癌患者不良预后的独立危险因素。
研究结论：
食管癌患者肿瘤细胞中高危型HPV DNA的高感染率和整合率使其E6/7癌蛋白持续性高表达,进而可能通过端粒酶相关基因hTERT和TRF2的DNA甲基化水平的改变,影响了端粒酶活性,逆转食管癌中端粒的进行性缩短,增加细胞的恶性转化和永生化,与食管癌患者的不良预后密切相关。
Background:
Esophageal squamous cell carcinoma (ESCC) is a common malignancy with high mortality and ranks as the fourth most frequent cause of cancer death in China as well as in worldwide. The Shantou of eastern Guangdong province, in southern China, is only one of coastal area with the high incidence of esophageal carcinoma (EC). The presence of (Human papillomavirus, HPV), mainly for high risk of HPV (HR-HPV), in cases of ESCC has been reported repeatedly about50-80%from Shantou, China, and other regions with a high incidence of esophageal carcinoma (EC). Thus, the role of high-risk HPV types in the carcinogenesis and prognosis of ESCC remains uncertain.
Telomeres and Telomerase, as the special structure at the ends of chromosomes, could maintain the stability, and prevent the degradation, abnormal terminal fusion or recombinant of chromosomal DNA. Telomere shortening and activation, which related with DNA methylation of telomere and subtelomere, is crucial in carcinogenesis and tumor progression. It's helpful for etiology study of EC to research the relationship between HPV infection and epigenetic mechanism.
Aim and Hypothesis:
Here, we fully explored the association among HR-HPV infection load and integration, telomere length (TL) and DNA methylation of telomerase related gene and submelomere, as well as their significance in the prognosis of ESCC, so as to provide some supplements to the etiology study of EC.
Our hypothesis as following:HR-HPV sustain infection in ESCC→HPV DNA breakage and its E6/7oncogene integration at the "fragile site" of the host chromosomes→The sustain and continuous expression of HPVE6/7oncoprotein→The changes of telomerase related gene (hTERT and TRF2) and subtelomere DNA methylation level→Effect of telomere length→Promotion of the malignant transformation and immortalization→Affect the prognosis of ESCC patients.
Method:
We established a stable and sensitive methodology of real time PCR to assess the prevalence, viral load and physical status of HR-HPV-16,-18and-58, infection the3most common HR-HPVs, as well as telomere length (LT) in patients with70cases of ESCC tumor (T) tissues and paired of paired nontumor (NT) tissues and50cases of normal esophagus (NE). DNA methylation and HPV-16protein expression were carried out by methylation-specific PCR (MSP) and using immunohistochemistry (IHC) assay, respectively. The prognostic value of TL and DNA methylation in ESCC was analyzed using SPSS16.0soft ware (SPSS Inc., Chicago, IL).
Results:
(1) All typical amplification plots involved HPV-16,-18and-58types for E2and E6/7plasmid DNA (change in the fluorescent signal versus cycle number). Six of standard curve showed a dynamic linear range for quantification across copy number over the entire range of dilution concentrations on bivariate correlation analysis (P<0.05).
(2) Widespread, but no difference of HR-HPV-16,-18and-58vial loads were found. The combined infection rates (50.00%vs.33.33%, P=0.045) and viral load (2.55±3.19vs.0.55±0.57copies/cell, P=0.029) for all HR-HPVs in ESCC patients was significantly higher than that of their corresponding controls. HPV DNA integration and mixed forms were more frequently observed in ESCC patients and in controls (91.43%vs.85.00%). The frequency of HR-HPV integration was higher than that for ESCC controls (F=17.832, P=0.001). The integration level was associated with pathological grade of ESCC (r=3.753, P=0.033). However, no significant associations were found between HPV physical status and patient age or lymph-node metastasis. HPV viral loads were not associated with ESCC patient age, lymph-node metastasis or cancer grade.
(3) IHC assay indicated that HPV-16protein expression, located mainly in the cytoplasm of cancer cells, was detected in59.26%of ESCC tissues and was positively correlated with pathological grade of cancer (r=0.301, P=0.027) in ESCC patients.
(4) TL decreased from normal esophagus mucosa, adjacent NT tissue to T tissue [4.77(4.28-5.33),4.37(3.89-5.09) and4.27(3.79-4.57) kb].
(5) T-TL was longer in ESCC samples positive for HPV (represented as low-risk HPV and HR-HPV) or HR-HPV. T-TL was positively correlated with viral load (r=0.410, P=0.037) and integration (r=0.492, P=0.01).
(6) Relatively long T-TL and high T/NT-TL ratio were frequently found with high viral load and integrated status. T/NT-TL was higher in ESCC patients with smoking, HPV infection or tumor grade III. T/NT-TL ratio was higher for surviving than non-surviving patients.
(7) Using MSP method, we found a hyper-methylation ratio (≥60%) for hTERT,7q,9q and XqYq but a hypo-methylation ratio (<40%) for TRF2,17q, and21q. we also found the concordant methylation level of7q and9q (r=0.304, P=0.011) and18q (r=0.311, P=0.009). The methylation level of hTERT and21q was negatively correlated with that of TRF2(r=-0.281, P=0.025, and r=-0.251, P=0.036, respectively).
(8) HR-HPV positivity increased the levels of hTERT,18q and21q methylation and decreased that of TFR2methylation. Furthermore, HR-HPV integration was positively correlated with hTERT methylation (r=0.413, P=0.036) and positively with TRF2methylation (r=0.453, P=0.02). However, HR-HPV viral load did not affect the ratio of hTERT, TRF2and subtelomere DNA methylation.
(9) High hTERT and21q methylation was more prevalent with long than short T-TL and was positively correlated with T-TL.
(10) Kaplan-Meier analysis and Univariate Cox regression analysis revealed significantly worse outcomes for patients with cancer grade Ⅲ (PHR=0.013), HR-HPV infection (PHR=0.037) and high T/NT-TL ratio (PHR=0.014). Multivariate survival analysis with a Cox proportional-hazards model revealed HR-HPV infection and high T/NT-TL ratio as the poor prognostic factors of survival, independent of age, gender, smoking, alcohol drinking, lymph node metastasis and cancer grade.
Summary:
(1) We established a stable and sensitive methodology of real time PCR to assess the viral load and physical status of HR-HPV-16,-18and-58DNA, as well as the relative telomere length.
(2) A relatively low HR-HPV copy number infection in ESCC is unlikely to play an essential a role in the carcinogenesis of ESCC. However, the mainly presentation of the physical status could sustain the high expression of the HR-HPV types in ESCC, which strongly suggests a possible role of oncogenic HPV infection in carcinogenesis of ESCC.
(3) TL gradually decreased in the process of esophageal carcinogenesis. HR-HPV infection could reverse the shortening of LT and maintain the TL in a critical length.
(4) DNA methylation levels of hTERT, TRF2and21q were participated in the maintenance of LT by HR-HPV infection.
(5) HR-HPV infection and high T/NT-TL ratio was the dependent of prognostic factors for the poor survival of ESCC.
Conclusion:
HR-HPV integration and expression related to telomere elongation and DNA methylation of hTERT and TRF2, may be a potential biomarker of prognosis in ESCC.
引文
[1]Jemal Al, Bray F, Center MM, et al. Global Cancer Statistics [J]. CA Cancer J Clin 2011,61(2):69-90.
[2]Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China,1990-2010: findings from the Global Burden of Disease Study 2010 [J]. Lancet 2013,381 (9882):1987-2015.
[3]Lim, Liu ZS, Chen ZF, et al. Mortality report of malignant tumors in Shexian, Hebei Province, China, from the 1970's to the present [J]. Asian Pac J Cancer Prev 2004,5(4):414-418.
[4]Awerkiew S, Bollschweiler E, Metzger R, et al. Esophageal cancer in Germany is associated with Epstein-Barr virus but not with papillomaviruses [J]. Med Microbiol Immunol (Berl) 2003,192(3):137-140.
[5]Lyronis ID, Baritaki S, Bizakis I, et al. Evaluation of the prevalence of human papillo-mavirus and Epstein-Barr virus in esophageal squamous cell carcinomas [J]. Int J Biol Markers 2005,20(1):5-10.
[6]Varnai AD, BollmannM, Griefingholt H, et al. HPV in anal squamous cell carcinoma and anal-intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis [J]. Int J Colorectal Dis 2006,21(2): 135-142.
[7]Senba M, Kumatori A, Fujita S, et al. The prevalence of human papillomavirus genotypes in penile cancers from Northern Thailand [J]. J Med Virol 2006,78(10): 1341-1346.
[8]Smith EM, Ritchie JM, Summersgill KF, et al. Age, sexual behavior and human papillo-mavirus infection in oral cavity and oropharyngeal cancers [J]. Int J Cancer 2004,108(5):766-772.
[9]Clifford GM, Smith JS, PlummerM, et al. Human papillomavirus types in invasive cervical cancer worldwide:a meta-analysis [J]. Br J Cancer 2003,88(1):63-73.
[10]Syrjanen KJ. HPV infections and esophageal cancer [J]. J Clin Pathol 2002,55(10): 721-728.
[11]Gao GF, Roth MJ, Wei WQ, et al. No association between HPV infection and the neoplastic progression of esophageal squamous cell carcinoma:Result from a cross -sectional study in a high-risk region of China [J]. Cancer 2006,119(6): 1354-1359.
[12]Zhu LZ, Su XL, Chen KN, et al. Detection rate of human papillomavirus-16 in esophageal squamous cell carcinoma from different Chinese populations [J]. Ai Zheng 2005,24(7):870-873.
[13]崔金环,杨光.人乳头瘤病毒与食管鳞癌的关系[J].肿瘤防治研究2007,6(34)：468-471.
[14]Wang He, Qiao YL. Human Papillomavirus Types and Their Related Diseases [J]. Acta Acad Med Sin 2007,29 (5):678-684.
[15]吕丽春,沈忠英,游绍进,沈健.汕头地区食管癌人乳头瘤状病毒的原位杂交检测[J].汕头大学医学院学报1995,2(1)：12-15.
[16]匡忠生,唐纯志,沈忠英.食管癌患者中HPV16,18的检测[J].广东医学2000,21(4)：305-306.
[17]Wang X, Tian X, Liu F, Zhao Y, Sun M, Chen D, et al. Detection of HPV DNA in esophageal cancer specimens from different regions and ethnic groups:a descriptive study [J]. Bmc Cancer 2010;10:19.
[18]Shen ZY, Hu SP, Lu LC, et al. Detection of human papillomavirus in esophageal carcinoma [J]. J Med Virol 2002,68(3):412-416.
[19]Zhang D, Zhang Q, Zhou L, et al. Comparison of prevalence, viral load, physical status and expression of human papillomavirus-16,-18 and -58 in esophageal and cervical cancer:a case-control study [J]. Bmc Cancer 2010,10:650.
[20]Zhang DH, Zhang QY, Hong CQ, et al. Prevalence and association of human papillomavirus 16, Epstein-Barr virus, herpes simplex virus-1 and cytomegalovirus infection with human esophageal carcinoma:a case-control study [J]. Oncol Rep 2011,25(6):1731-1738.
[21]Zhang QY, Zhang DH, Shen ZY, Xu LY, Li EM, Au WW. Infection and integration of human papillomavirus in esophageal carcinoma [J]. Int J Hyg Environ Health 2011,214(2):156-161.
[22]Qi Z, Xu X, Zhang B, et al. Effect of simultaneous silencing of HPV-18 E6 and E7 on inducing apoptosis in HeLa cells [J]. Biochem Cell Biol 2010, 88(4):697-704.
[23]Zur Hausen H. Papillomavirus infections-a major cause of human cancers [J]. Biochim Biophys Acta 1996,1288 (2):F55-F78.
[24]沈忠英,蔡维佳,许锦阶,等.人乳头瘤病毒18 E6、E7和TPA协同诱发人胚食管上皮细胞恶性转化的研究[J].病毒学报1999,15(1)：1-5.
[25]Vinokurova S, Wentzensen N, Kraus I, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions [J]. Cancer Res 2008,68(1): 307-313.
[26]Zhou XB, Xu NZ. Current advances in the mechanic studies of human papillomavirus induced oncogenesis [J]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2007,29(5):673-677.
[27]De Lange T. Shelterin:the protein complex that shapes and safeguards human telomeres [J]. Genes Dev 2005,19 (18):2100-2110
[28]Flores I, Cayuela ML, Blasco MA. Effects of telomerase and telomere length on epidermal stem cell behavior [J]. Science 2005,309 (5738):125321256
[29]Kim M K, Kang MR, Nam HW, et al. Regulation of telomeric repeat binding factor 1 binding to telomeres by casein kinase 22 mediated phosphorylation [J]. J Biol Chem 2008,283(20):14144-52.
[30]Loayza D, de Lange T. POT1 as a terminal transducer of TRF1 telomere length control [J]. Nature,2003,423 (6943):1013-1018.
[31]Bailey SM. Telomeres and double-strand breaks 2 all's well that "ends" well [J]. Radiat Res 2008,169 (1):127.
[32]van Overbeek M, de Lange T. Apollo, an artemis-related nuclease, interacts with TRF2 and protects human telomeres in S Phase [J]. Curr Biol 2006,16 (13):1295-1302.
[33]Gonzalo S, Jaco I, Fraga MF, et al. DNA methyltransferases control telomere length and telomere recombination in mammalian cells [J]. Nat Cell Biol 2006, 8(4):416-424.
[34]Ottaviani A, Gilson E, Magdinier F. Telomeric position effect:From the yeast paradigm to human pathologies [J]. Biochimie 2008,90(1):932107.
[35]Arias-Pulido H, Peyton CL, Joste NE, Vargas H, Wheeler CM. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer [J]. J Clin Microbiol 2006,44(5):1755-1762.
[36]Guo M, Sneige N, Silva EG, Jan YJ, Cogdell DE, Lin E, Luthra R, Zhang W: Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma [J]. Modern Pathology 2007,20(2):256-266.
[37]Cawthon RM. Telomere measurement by quantitative PCR [J]. Nucleic Acids Res 2002; 30(10):e47.
[38]Dong W, Wang L, Chen X, Sun P, Wu Y. Upregulation and CpG island hypomethylation of the TRF2 gene in human gastric cancer [J]. Dig Dis Sci 2010, 55(4):997-1003.
[39]Oh BK, Urn TH, Choi GH, Park YN. Frequent changes in subtelomeric DNA methylation patterns and its relevance to telomere regulation during human hepatocarcinogenesis [J]. Int J Cancer 2011,128(4):857-68.
[40]Lee ME, Rha SY, Jeung HC, Chung HC, Oh BK. Subtelomeric DNA methylation and telomere length in human cancer cells [J]. Cancer Lett 2009,281(1):82-91.
[41]Jiang J, Zhao LJ, Zhao C, Zhang G, Zhao Y, Li JR, et al. Hypomethylated CpG around the transcription start site enables TERT expression and HPV 16 E6 regulates TERT methylation in cervical cancer cells [J]. Gynecol Oncol 2012, 124(3):534-41.
[42]吕丽春,沈忠英,邱向南,唐纯志,沈健,蔡唯佳.高低发区食管癌组织人乳头状瘤病毒的PCR检测[J].癌症1997,16(5)：341-342.
[43]Feng S, Zheng J, Du X, Tan Y, Yang H, Zhang H, Zhang Z. Human papillomavirus was not detected by PCR using multiple consensus primer sets in esophageal adenocarcinomas in Chinese patients [J]. J Med Virol 2013, 85(6):1053-7.
[44]Liu HY, Zhou SL, Ku JW, Zhang DY, Li B, et al. Prevalence of human papillomavirus infection in esophageal and cervical cancers in the high incidence area for the two diseases from 2007 to 2009 in Linzhou of Henan Province, Northern China [J]. Arch Virol.2014 Jan 3. [Epub ahead of print]
[45]Li X, Gao C, Yang Y, et al. Systematic review with meta-analysis:the association between human papillomavirus infection and oesophageal cancer [J]. Aliment Pharmacol Ther 2014,39(3):270-81
[46]Antunes LC, Prolla JC, de Barros Lopes A, et al. No evidence of HPV DNA in esophageal squamous cell carcinoma in a population of Southern Brazil [J]. World J Gastroenterol 2013,19(39):6598-603.
[47]Yong F, Xudong N, Lijie T. Human papillomavirus types 16 and 18 in esophagus squamous cell carcinoma:a meta-analysis [J]. Ann Epidemiol 2013, 23(11):726-34
[48]Liyanage SS, Rahman B, Ridda I, et al. The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma:a meta-analysis [J]. PLoS One 2013,24;8(7):e69238
[49]Haeri H, Mardany O, Asadi-Amoli F, Shahsiah R. Human papilloma virus and esophageal squamous cell carcinoma [J]. Acta Med Iran 2013,51(4):242-5.
[50]Feng S, Zheng J, Du X, et al. Human papillomavirus was not detected by PCR using multiple consensus primer sets in esophageal adenocarcinomas in Chinese patients [J]. J Med Virol 2013,85(6):1053-7.
[51]Williams VM, Filippova M, Filippov V, et al. HPV16 E6* induces oxidative stress and DNA damage [J]. J Virol 2014 Apr 2. [Epub ahead of print]
[52]Vega-Pena A, Illades-Aguiar B, Flores-Alfaro E, et al. Risk of progression of early cervical lesions is associated with integration and persistence of HPV-16 and expression of E6, Ki-67, and telomerase [J]. J Cytol 2013,30(4):226-32.
[53]Pretet JL, Charlot JF, Mougin C. Virological and carcinogenic aspects of HPV [J]. Bull Acad Natl Med 2007,191(3):611-23;
[54]Hamid NA, Brown C, Gaston K. The regulation of cell proliferation by the papillomavirus early proteins [J]. Cell Mol Life Sci 2009,66(10):1700-17.
[55]Kahla S, Kochbati L, Maalej M, et al. Situation of HPV 16 E2 Gene Status During Radiotherapy Treatment of Cervical Carcinoma [J]. Asian Pac J Cancer Prev 2014,15(6):2869-73.
[56]Badaracco G, Venuti A, Sedati A, et al. HPV-16 and HPV-18 in genital tumors: significantly different levels of viral integration and correlation to tumor invasiveness [J]. J Med Virol 2002,67(4):574-582
[57]Das BC, Sharma JK, Gopalakrishna V, et al. Analysis by polymerase chain reaction of the physical state of human papillomavirus type 16 DNA in cervical preneoplastic and neoplastic lesions [J]. Gen Virol 1992,73(Pt9):2327-2336
[58]Zhang LD, Zhang HM, et al. Investigation on HPV viral load and high risk HPV types infection among patients with infertility [J]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2007,21(2):159-161.
[59]牛永东,李恩民,吴贤英,郑瑞明,沈忠英,许丽艳.食管鳞癌中HPV-16/-18感染c-erb B-2、p53和Rb表达及其意义[J].肿瘤防治杂志2002,9(2)：138-141.
[60]Feng WJ, Danielle WL, Martin RJ, et al. Quantitation of Human papillomavirus 16 E6 and E7 Thin-Prep Papanicolaou Tests Using Real-Time Polymerase Chain Reaction Analysis [J]. Cancer 2002,94(15):2199-2209.
[61]Thorland EC, Myers SL, Persing DH, et al. Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites [J]. Cancer Res 2000,60(21):5916-5921.
[62]Klimov E, Vinokourova S, Moisjak E, et al. Human papillomaviruses and cervical tumors:mapping of integration sites and analysis of adjacent cellular sequences [J]. BMC Cancer 2002,13(2):24.
[63]Shay JW. Molecular pathogenesis of aging and cancer:are telomeres and telomerase the connection [J]. J Clin Pathol 1997,50(10):799-800.
[64]Hsu CP, Lee LW, Shai SE, Chen CY. Clinical significance of telomerase and its associate genes expression in the maintenance of telomere length in squamous cell carcinoma of the esophagus [J]. World J Gastroenterol 2005, 11(44):6941-7.
[65]Queisser A, Heeg S, Thaler M, von Werder A. Inhibition of telomerase induces alternative lengthening of telomeres during humanesophageal carcinogenesis [J]. Cancer Genet 2013,206(11):374-86
[66]Lin SW, Abnet CC, Freedman ND, et al. Measuring telomere length for the early detection of precursor lesions of esophageal squamous cell carcinoma [J]. BMC Cancer 2013,5;13:578.
[67]Pal J, Gold JS, Munshi NC, Shammas MA. Biology of telomeres:importance in etiology of esophageal cancer and as therapeutic target [J]. Transl Res 2013, 162(6):364-70.
[68]Cesare AJ, Reddel RR. Telomere uncapping and alternative lengthening of telomeres [J]. Mech Ageing Dev 2008,129(1):99-108.
[69]Tatsumoto N, Hiyama E, Murakami Y, et al. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer [J]. Clin Cancer Res 2000,6(7):2696-701.
[70]Lu L, Zhang C, Zhu G, et al. Telomerase expression and telomere length in breast cancer and their associations withadjuvant treatment and disease outcome [J]. Breast Cancer Research 2011,13(3):R56.
[71]Oh BK1, Kim H, Park YN, et al. High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis [J]. Laboratory Investigation 2008,88(2):144-152.
[72]Shen ZY, Xu LY, Li EM, et al. The multistage process of carcinogenesis in human esophageal epithelial cells induced by human papillomavirus [J]. Oncol Rep 2004,11(3):647-54.
[73]Shen ZY, Xu LY, Li C, Cai WJ, Shen J, Chen JY, et al.. A comparative study of telomerase activity and malignant phenotype in multistage carcinogenesis of esophageal epithelial cells induced by human papillomavirus [J]. Int J Mol Med 2001,8(6):633-9.
[74]郭艳合,张义玲,刘立,等.哺乳动物细胞衰老调节的新机制——端粒的表观遗传修饰[J].中国生物化学与分子生物学报2008,24(10)：895-901.
[75]李伟,陶凯雄hTERT表达的表观遗传调控研究进展[J].世界华人消化杂志2010,18(10)：1026-1031.
[76]Marciniak R A, Cavazos D, Montellano R, et al. A novel telomere structure in a human alternative lengthening of telomeres cell line [J]. Cancer Res 2005,65 (7):2730-2737.
[77]Okano M, Bell DW, Haber DA, et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development [J]. Cell 1999,99 (3):247-257.
[78]Gonzalo S, Jaco I, Fraga MF, et al. DNA methyltransferases control telomere length and telomere recombination in mammalian cells [J]. Nat Cell Biol 2006,8 (4):416-424.
[79]Kong CM, Lee XW, Wang X. Telomere shortening in human diseases [J]. FEBS J 2013,280(14):3180-93.
[80]Pal J, Gold JS, Munshi NC, Shammas MA. Biology of telomeres:importance in etiology of esophageal cancer and as therapeutic target [J]. Transl Res 2013, 162(6):364-70
[81]Gunes C, Rudolph KL. The role of telomeres in stem cells and cancer [J]. Cell 2013,152(3):390-3.
[1]Grieder C, Blackburn E. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts [J]. Cell,1985,43 (2 Pt 1):405-13.
[2]Vogel G, Pennisi E. Physiology Nobel. U.S. Researchers recognized for work on telomeres. Science,2009; 326 (5950):212-213.
[3]Harrington L. Those dam-aged telomeres! [J]. Curr Opin Genet Dev,2004,14 (1):22-8
[4]Shin JS, Hong A, Solomon MJ, et al. The role of telomeres andtelomerase in the pathology of human cancer and aging [J]. Pathology,2006,38(2):103-113.
[5]Djojosubroto MW, Choi YS, Lee HW, et al. Telomeres and telomerase in aging, regeneration and cancer [J]. Mol Cells,2003,15 (2):164-175.
[6]Gilley D, Tanaka H, et al. Telomere dysfunction in aging and cancer [J]. The International Journal of Biochemistry CellBiology,2005,37(5):1000-1013.
[7]Marusic L, AntonM, Tidy A, et al. Reprogramming of telomerase by expression of mutant telomerase RN A template in human cells leads to altered telomeres that correlate with reducde cell viability [J]. Mol Cell Biol,1997,17(11):6394-6401.
[8]Mergny JL, Riou JF, Mailliet P, et al. Natural and pharmacological regulation of telomerase [J]. Nucleic Acids Res,2002,30(4):839-865.
[9]Blasco MA. Telomeres and human disease:ageing, cancer and beyond [J]. Nature Review,2005,6 (8):611-622.
[10]De Lange T. Shelterin:the protein complex that shapes and safeguards human telomeres [J]. Genes Dev,2005,19 (18):2100-2110.
[11]Hsiao SJ, Smith S. Tankyrase function at telomeres, spindle poles, and beyond [J]. Biochimie,2008,90(1):83-92.
[12]Kim MK, Kang MR, Nam HW, et al. Regulation of telomeric repeat binding factor 1 binding to telomeres by casein kinase 22 mediated phosphorylation [J]. J Biol Chem,2008,283(20):14144-52.
[13]Loayza D, de Lange T. POT1 as a terminal transducer of TRF1 telomere length control [J]. Nature,2003,423(6943):1013-1018.
[14]Bailey SM. Telomeres and double strand breaks 2 alls well that "ends" well [J]. Radiat Res,2008,169(1):127.
[15]van Overbeek M, de Lange T. Apollo an artemis related nuclease, interacts with TRF2 and protects human telomeres in S Phase [J]. Curr Biol,2006,16 (13): 1295-1302.
[16]Dimitrova N, de Lange T. MDC1 accelerates nonhomologous end joining of dysfunctional telomeres [J]. Genes Dev,2006,20(23):3238-3243.
[17]Denchi EL, de Lange T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1 [J]. Nature,2007,448 (7157):1068-1071.
[18]Karlseder J. Telomere repeat binding factors:keeping the ends in check [J]. Cancer Lett,2003,194(2):189-197.
[19]Ohki R, Ishikawa F. Telomere-bound TRF1 and TRF2 stall the replication fork at telomeric repeats [J]. Nucleic Acids Res,2004,32 (5):1627-1637.
[20]Karlseder J, Broccoli D, Dai Y, et al. p53-and ATM-dependent apoptosis induced by telomeres lacking TRF2 [J]. Science,1999,283 (5406):1321-1325.
[21]Gomez M, Wu J, Schreiber V, et al. PARP1 Is a TRF2-associated poly (ADP-ribose) polymerase and protects eroded telomeres [J]. Mol Biol Cell,2006, 17(4):1686-1696.
[22]Feng J, Funk W D, Wang S S, et al. The RNA component of human telomerase [J]. Science,1995,269(5228):1236-1241.
[22]Ren X, Gavory G, Li H, et al. Identification of a new RNA.RNA interaction site for human telomerase RNA (hTR):structuralimplications for hTR accumulation and a dyskeratosis congenital point mutation [J]. Nucleic Acids Res,2003,31(22): 6509-6515.
[24]Chen JL, Greider CW. Template boundary definition in mammalian telomerase [J]. Genes Dev,2003(22),17:2747-2752.
[25]Tzfati Y, Fulton TB, Roy J, et al. Template boundary in a yeast telomerase specified by RNA structure [J]. Science,2000,288(5467):863-867.
[26]Uchida N, Otsuka T, Shigematsu H, et al. Differential gene expression of human telomerase-associated protein hTERT andTEP1 in human hematopoietic cells [J]. Leuk Res,1999,23(12):1127-1132.
[27]Kickhoefer VA, Liu Y, Kong L B, et al. The Telomerase/vault-associated protein TEP1 is required for vault RNA stability and its association with the vault particle [J]. J Cell Biol,2001,152(1):157-164.
[28]Theimer CA, Feigon J. Structure and function of telomerase RNA [J]. Curr Opin Struct Biol,2006,16(3):307-318.
[29]Autexier C, Lue NF. The structure and function of telomerase reverse transcriptase [J]. Annu Rev Biochem,2006,75:493-517.
[30]Chang JT, Chen YL, Yang HT, et al. Differential regulation of telomerase activity by six telomerase subunits [J]. Eur J Biochem,2002,269(14):3442-3450.
[31]Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells [J]. Cell,2003,114(2):241-253.
[32]Okuda K, Bardeguez A, Gardner JP, et al. Telomere length in the newborn [J]. Pediatric Research,2002,52(3):377-381.
[33]Butler MG, Tilburt J, DeVries A, et al. Comparison of chromosometelomere integrity inmultiple tissues from subjects at different ages [J]. Cancer Genetics and Cytogenetics,1998,105(2):138-144.
[34]Benetos A, Okuda K, Lajemi M, et al. Telomere length as an indicator of biological aging:the gender effect and relation with pulse pressure andpulse wave velocity [J]. Hypertension,2011,37(2):381-385.
[35]Misiti S, Nanni S, Fontemaggi G, et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells [J]. Molecular and Cellular Biology,2000,20(11):3764-3771.
[36]陈宇,张伟丽,惠汝太.染色体端粒损耗与心血管病及血管危险因子的关系[J].中国分子心脏病学杂志,2009(4)：246-249.
[37]Bekaert S, De Meyer T, Rietzsehel ER, et al. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease [J]. Aging Cell,2007,6(5):639-647.
[38]Zglinicki TV. Oxidative stress shortens telomeres [J]. Trends in Biochemical science,2002,27(7):339-344.
[39]Matthews C, Gorenne I, Scott S, et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis:effects of telomerase and oxidative stress [J]. Circulation Research,2006,99(2):156-164.
[40]Haendeler J, Hoffmann J, Diehl JF, et al. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells [J]. Circulation Research,2006,94(6):768-775.
[41]Nawrot TS, Staessen JA, Holvoet P, et al. Telomere length and its associations with oxidized-LDL, carotid artery distensibility and smoking [J]. Front. Bioscience,2010,2:1164-1168.
[42]Xu D, Erickson S, Szeps M, et al. Interferon a down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells [J]. Blood,2000,96(13):4313-4318.
[43]Aisner DL, Wright WE, Shay JW. Telomerase regulation:not just flipping the switch [J]. Curr Opin Genet Dev,2002(1),12:80-85.
[44]Collins K, Mitchell JR. Telomerase in the human organism [J]. Oncogene,2002, 21(4):564-579.
[45]Blasco MA. Mammalian telomeres and telomerase:why they matter for cancer and aging [J]. Eur J Cell Biol,2003,82(9):441-446.
[46]Shay JW, Bacchetti S. A survey of telomerase activity in human cancer [J]. Eur J Cancer,1997,33(5):787-791.
[47]Cerone MA, Londono-Vallejo JA, Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells [J]. Hum Mol Genet, 2001,10(18):1945-1952.
[48]Bailey SM, Brenneman MA, Goodwin EH. Frequent recombination in telomeric DNA may extend the proliferative life of telomerase-negative cells [J]. Nucleic Acids Res,2004,32(12):3743-3751.
[49]de The H, Lavau C, Marchio A, et al. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR [J]. Cell,1991,66(4):675-684.
[50]Londono-Vallejo JA, Der-Sarkissian H, Cazes L, et al. Alternative lengthening of telomeres is characterized by high rates of telomeric exchange [J]. Cancer Res, 2004,64(7):2324-2327.
[50]Mason JM, Konev AY, Biessmann H. Telomeric position effect in 55'drosophila melanogaster reflects a telomere length control mechanism [J]. Genetica,2003, 117(2-3):319-325.
[51]巩燕,房殿春.端粒位置效应与人类衰老[J].细胞生物学杂志,2004,26：513-515.
[52]Baur JA, Zou Y, Shay JW, et al. Telomereposition effect in human cells [J]. Science,2001,292(5524):2075-2077.
[53]Karlseder J, Smogorzewska A, de Lange W, et al. Senescence induced by altered telomere state, not telomere loss [J]. Science,2002,295(5564):2446-2449.
[54]Ottaviani AGilson E, Magdinier E. Telomeric position effect:from the yeast paradigm to human pathologies?[J]. Biochimie,2008,90(1):93-107.
[55]Doheny JG, Mottus R, Grigliatti TA. Telomeric position effect a third silencing mechanism in eukaryotes [J]. PLoS ONE,2008,3(12):3864.
[56]Bilaud T, Brun C, Ancelin K, et al. Telomeric localization of TRF2, anovel human telobox protein [J]. Nat Genet,1997,17(2):236-239.
[57]Donigian JR, de Lange T. The role of the poly (ADP-ribose) polymerase tankyrasel in telomere Length control by the TRF1 component of the sheherin complex [J]. J Biol Chem,2007,282(31):22662-22667.
[58]Kim H, Lee O H, Xin H, et al. TRF2 functions as aprotein hub and regulates telomere maintenance by recognizing specific peptide motifs [J]. Nat Struct Mol Biol,2009,16(4):372-379.
[59]Chiang YJ, Kim S H, Tessarollo L, et al. Telomere-associated protein TIN2 is essential for early embryonic development through a telomerase-independent pathway [J]. Mol Cell Biol,2004,24(15):6631-6634.
[60]Sfeir A, Kabir S, vall Overbeek M, et al. Loss of Rapl induces telomere recombination in the absence of NHEJ or a DNA damage signal [J]. Science, 2010,327 (5973):1657-1661.
[61]Tejera AM, Stagno DM, Thanasoula M, et al. TPP1 is required for TERT recruitment, telomere elongation during nuclear reprogramming, and normal skin development in mice [J]. Dev Cell,2010,18(5):775-789.
[62]Wu L, Muhani AS, He H, et al. PotI deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres [J]. Cell,2006,126(1):49-62.
[63]Marciniak RA, Cavazos D, Montellano R, et al. A novel telomere structure in a human alternative lengthening of telomeres cell line [J]. Cancer Res,2005,65 (7): 2730-2737.
[64]Okano M, Bell DW, Haber DA, et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development [J]. Cell,1999,99 (3):247-257.
[65]Gonzalo S, Jaco I, Fraga MF, et al. DNA methyltransferases control telomere length and telomere recombination in mammalian cells [J]. Nat Cell Biol,2006, 8(4):416-424.
[67]Gonzalo S, Garcia-Cao M, Fraga MF, et al. Role of the RBI familyin stabilizing histone methylation at constitutive heterochromatin [J]. Nat Cell Biol,2005,7 (4): 420-428
[68]Benetti M, Garcia-Cao M, Blasco MA. Telomere length regulatesthe epigenetic status of mammalian telomeres and subtelomeres [J]. Nat Genet,2007,39 (2): 243-250.
[69]Venturini L, Daidone MG, Motta R, et al. Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors:expression and prognostic relevance [J]. Neuro-Oncology,2012,14(6):736-744.
[70]Saini N, Srinivasan R, Chawla Y. Et al. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status [J]. Liver International,2009,29(8):1162-70.
[71]PM Lansdorp NP, Verwoerd FM, Van de Pijike, et al. Heterogeneity in telomere length of hmnan chromosomes [J]. Hum. Mol. Genet.1996,5(5):685-91.
[72]McNeil N, Ried T. Novel molecular cytogenetic techniques for identifying complex chromosomal rearrangements:technology and applications in molecular medicine [J]. Expert Rev. Med,2000,2000:1-14.
[73]Baerlocher GM, Mak J, Tien T, et al. Telomere length messurment by fluorescence in situ hybridization and flow cytometry:tips and pitfalls [J]. Cytomcuy,2002,47(2):88-99.
[74]Gil ME, Coetzer TL. Real-time quantitative PCR of telomere length [J]. Molecular Biotechnology,2004,27(2):169-172.
[75]Lu LG, Zhang, Zhu GJ, et al. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome [J]. Breast Cancer Research,2011,13(3):R56
[76]Artandi SE, DePinho RA. Telomeres and telomerase in cancer [J]. Carcinogenesis,2010,31(1):9-18.
[77]Shin JS, Hong A, Solomon MJ, et al. The role of telomeres and telomerase in the pathology of human cancer and aging [J]. Pathology,2006,38(2):103-13.
[78]Giines C, Rudolph KL. The role of telomeres in stem cells and cancer [J]. Cell, 2013,152(3):390-3.
[79]Kong CM, Lee XW, Wang X. Telomere shortening in human diseases [J]. FEBS J, 2013,280(14):3180-93.
[80]Saleh S, Lam AK, Ho YH. Real -time PCR quantification of human telomerase reverse transcriptase (hTERT) in colorectal cancer [J]. Pathology,2008,40 (1):25-30.
[81]Rampazzo E, Bertorelle R, Serra L, Terrin L, Candiotto C, Pucciarelli S, et al. Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers [J]. Br J Cancer,2010,102(8):1300-5.
[81]Abbott A. Chromosome protection scoops Nobel [J]. Nature,2009,461(7265): 706-707.
[82]Tatsumoto N, Hiyama E, Murakami Y, et al. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer [J]. Clin Cancer Res,2000,6(7):2696-701.
[83]Lu L, Zhang C, Zhu G, et al. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome [J]. Breast Cancer Research,2011,13(3):R56.
[84]Oh BK, Kim H, Park YN, et al. High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis [J]. Laboratory Investigation,2008,88(2):144-152.
[85]Pal J, Gold JS, Munshi NC, Shammas MA. Biology of telomeres:importance in etiology of esophageal cancer and as therapeutic target [J]. Transl Res,2013, 162(6):364-370.
[86]Risques RA, Vaughan TL, Li X, et al. Leukocyte telomere length predicts cancer risk in Barrett's esophagus [J]. Cancer Epidemiol Biomarkers Prev,2007,16 (12): 2649-2655.
[87]Xing J, Ajani JA, Chen M, et al. Constitutive short telomere length of chromosome 17p and 12q but not llq and 2p is associated with an increased risk for esophageal cancer [J]. Cancer Prev Res (Phila),2009,2 (5):459-465.
[88]Feng S, Zheng J, Du X, et al. Human papillomavirus was not detected by PCR using multiple consensus primer sets in esophageal adenocarcinomas in Chinese patients [J]. J Med Virol,2013,85(6):1053-1057.
[89]Liu HY, Zhou SL, Ku JW, et al. Prevalence of human papillomavirus infection in esophageal and cervical cancers in the high incidence area for the two diseases from 2007 to 2009 in Linzhou of Henan Province, Northern China [J]. Arch Virol. 2014 Jan 3. [Epub ahead of print].
[90]Li X, Gao C, Yang Y, et al. Systematic review with meta-analysis:the association between human papillomavirus infection and oesophageal cancer [J]. Aliment Pharmacol Ther,2014,39(3):270-81
[91]Antunes LC, Prolla JC, de Barros Lopes A, et al. No evidence of HPV DNA in esophageal squamous cell carcinoma in a population of Southern Brazil [J]. World J Gastroenterol,2013,19(39):6598-603.
[92]Zhang H, Jin Y, Chen X, et al. Papillomavirus type 16 E6/E7 and human telomerase reverse transcriptase in esophageal cell immortalization and early transformation [J]. Cancer Lett,2007,245(1-2):184-94.
[93]Hsu CP, Lee LW, Shai SE, et al. Clinical significance of telomerase and its associate genes expression in the maintenance of telomere length in squamous cell carcinoma of the esophagus [J]. World J Gastroenterol,2005,11(44):6941-6917.
[94]Liu X, Dakic A, Zhang Y, et al. HPV E6 protein interacts physically and functionally with the cellular telomerase complex [J]. Proc Natl Acad Sci USA, 2009,106(44):18780-18785.
[95]Pooley KA, Sandhu MS, Tyrer J, et al. Telomere length in prospective and retrospective cancer case-control studies [J]. Cancer Res,2010,70 (8):3170-3176.
[96]Rampazzo E, Bertorelle R, Serra L, et al. Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers [J]. Br J Cancer,2010,102(8):1300-5.
[97]Frias C, Pampalona J, Genesca A, et al. Telomere dysfunction and genome instability [J]. Front Biosci,2012,17:2181-2196.
[98]Begus-Nahrmann Y, Hartmann D, Kraus J, et al. Transient telomere dysfunction induces chromosomal instability and promotes carcinogenesis [J]. J Clin Invest, 2012,122(6):2283-2288.
[99]Perera SA, Maser RS, Xia H, et al. Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer [J]. Carcinogenesis,2008,29 (4):747-753.
[100]Jones AM, Beggs AD, Carvajal-Carmona L, et al. TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres [J]. Gut,2012,61(2):248-254.
[101]Lan Q, Cawthon R, Shen M, et al. A prospective study of telomere length measured by monochrome multiplex quantitative PCR and risk of non-Hodgkin lymphoma [J]. Clin Cancer Res,2009,15(23):7429-7433.
[102]Artandi SE, DePinho RA. Telomeres and telomerase in cancer [J]. Carcinogenesis,2010,31(1):9-18.
[103]Cui Y, Cai Q, Qu S, et al. Association of leukocyte telomere length with colorectal cancer risk:Nested case-control findings from the Shanghai women's health study [J]. Cancer Epidemiol Biomarkers Prev,2012,21(10):1807-1813.
[104]Mu Y, Zhang Q, Mei L, et al. Telomere shortening occurs early during gastrocarcinogenesis [J]. Med Oncol,2012,29(2):893-898.
[105]Liu X, Bao G, Huo T, et al. Constitutive telomere length and gastric cancer risk: case-control analysis in Chinese Han population [J]. Cancer Sci,2009,100 (7): 1300-1305.
[106]Hou L, Savage SA, Blaser MJ, et al. Telomere length in peripheral leukocyte DNA and gastric cancer risk [J]. Cancer Epidemiol Biomarkers Prev,2009, 18(11):103-3109.
[107]Hu H, Zhang Y, Zou M, et al. Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is associated with telomere shortening and may contribute to multistage carcinogenesis of Gastric cancer [J]. J Cancer Res Clin Oneol,2010, 136(9):1407-1414.
[108]Wan SM, Tie J, Zhang YF, et al. Silencing of the hPOT1 gene by RNA inference promotes apoptosis and inhibits proliferation and aggressive phenotype of gastric cancer cells, likely through up-regulating PinXl expression [J]. J Clin Pathol, 2011,64(12):1051-1057.
[109]Gao J, Zhang J, Long Y, et al. Expression of telomere binding proteins in gastric cancer and correlation with clinicopathological parameters [J]. Asia Pac J Clin Oncol,2011,7(4):339-345.
[110]Yao DF, Wu W, Yao M, et al. Dynamic alteration of telomerase expression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma [J]. World J Gastroenterol,2006,12(31):4966-4972.
[111]Oh BK, Kim YJ, Park C, et al. Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis [J]. Am J Pathol,2005,166(1):73-80.
[112]Oh BK, Kim H, Park YN, et al. High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis [J]. Lab Invest,2008, 88(2):144-52.
[113]Guo Y, Zhuo X, Liu E, et al. Difference in hTERT gene expressions between HBsAg-positive and HBsAg-negative hepatocellular carcinoma [J]. J Hua zhong Univ Sci Technolog Med Sci,2005,25(3):303-306.
[114]OH BK, Kim YJ, Park YN, et al. Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis [J]. Am J Gastroenterol,2006,101(4):831-838.
[115]Qu ZL, Zou SQ, Cui NQ, et al. Upregulation of human telomerase reverse transcriptase mRNA expression by in vitro transfection of hepatitis B virus X gene into human hepatocarcinoma and cholangiocarcinoma cells [J]. World J Gastroenterol,2005, 11(36):5627-5632.
[116]Skinner HG, Gangnon RE, Litzelman K, et al. Telomere length and pancreatic cancer:a case-control study [J]. Cancer Epidemiol Biomarkers Prev,2012,21 (11):2095-2100.
[117]Seimiya H, Muramatsu Y, Ohishi T, et al. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics [J]. Cancer Cell,2005,7(1):25-37.
[2]Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China,1990-2010: findings from the Global Burden of Disease Study 2010 [J]. Lancet 2013,381 (9882):1987-2015.
[3]Lim, Liu ZS, Chen ZF, et al. Mortality report of malignant tumors in Shexian, Hebei Province, China, from the 1970's to the present [J]. Asian Pac J Cancer Prev 2004,5(4):414-418.
[4]Awerkiew S, Bollschweiler E, Metzger R, et al. Esophageal cancer in Germany is associated with Epstein-Barr virus but not with papillomaviruses [J]. Med Microbiol Immunol (Berl) 2003,192(3):137-140.
[5]Lyronis ID, Baritaki S, Bizakis I, et al. Evaluation of the prevalence of human papillo-mavirus and Epstein-Barr virus in esophageal squamous cell carcinomas [J]. Int J Biol Markers 2005,20(1):5-10.
[6]Varnai AD, BollmannM, Griefingholt H, et al. HPV in anal squamous cell carcinoma and anal-intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis [J]. Int J Colorectal Dis 2006,21(2): 135-142.
[7]Senba M, Kumatori A, Fujita S, et al. The prevalence of human papillomavirus genotypes in penile cancers from Northern Thailand [J]. J Med Virol 2006,78(10): 1341-1346.
[8]Smith EM, Ritchie JM, Summersgill KF, et al. Age, sexual behavior and human papillo-mavirus infection in oral cavity and oropharyngeal cancers [J]. Int J Cancer 2004,108(5):766-772.
[9]Clifford GM, Smith JS, PlummerM, et al. Human papillomavirus types in invasive cervical cancer worldwide:a meta-analysis [J]. Br J Cancer 2003,88(1):63-73.
[10]Syrjanen KJ. HPV infections and esophageal cancer [J]. J Clin Pathol 2002,55(10): 721-728.
[11]Gao GF, Roth MJ, Wei WQ, et al. No association between HPV infection and the neoplastic progression of esophageal squamous cell carcinoma:Result from a cross -sectional study in a high-risk region of China [J]. Cancer 2006,119(6): 1354-1359.
[12]Zhu LZ, Su XL, Chen KN, et al. Detection rate of human papillomavirus-16 in esophageal squamous cell carcinoma from different Chinese populations [J]. Ai Zheng 2005,24(7):870-873.
[13]崔金环,杨光.人乳头瘤病毒与食管鳞癌的关系[J].肿瘤防治研究2007,6(34)：468-471.
[14]Wang He, Qiao YL. Human Papillomavirus Types and Their Related Diseases [J]. Acta Acad Med Sin 2007,29 (5):678-684.
[15]吕丽春,沈忠英,游绍进,沈健.汕头地区食管癌人乳头瘤状病毒的原位杂交检测[J].汕头大学医学院学报1995,2(1)：12-15.
[16]匡忠生,唐纯志,沈忠英.食管癌患者中HPV16,18的检测[J].广东医学2000,21(4)：305-306.
[17]Wang X, Tian X, Liu F, Zhao Y, Sun M, Chen D, et al. Detection of HPV DNA in esophageal cancer specimens from different regions and ethnic groups:a descriptive study [J]. Bmc Cancer 2010;10:19.
[18]Shen ZY, Hu SP, Lu LC, et al. Detection of human papillomavirus in esophageal carcinoma [J]. J Med Virol 2002,68(3):412-416.
[19]Zhang D, Zhang Q, Zhou L, et al. Comparison of prevalence, viral load, physical status and expression of human papillomavirus-16,-18 and -58 in esophageal and cervical cancer:a case-control study [J]. Bmc Cancer 2010,10:650.
[20]Zhang DH, Zhang QY, Hong CQ, et al. Prevalence and association of human papillomavirus 16, Epstein-Barr virus, herpes simplex virus-1 and cytomegalovirus infection with human esophageal carcinoma:a case-control study [J]. Oncol Rep 2011,25(6):1731-1738.
[21]Zhang QY, Zhang DH, Shen ZY, Xu LY, Li EM, Au WW. Infection and integration of human papillomavirus in esophageal carcinoma [J]. Int J Hyg Environ Health 2011,214(2):156-161.
[22]Qi Z, Xu X, Zhang B, et al. Effect of simultaneous silencing of HPV-18 E6 and E7 on inducing apoptosis in HeLa cells [J]. Biochem Cell Biol 2010, 88(4):697-704.
[23]Zur Hausen H. Papillomavirus infections-a major cause of human cancers [J]. Biochim Biophys Acta 1996,1288 (2):F55-F78.
[24]沈忠英,蔡维佳,许锦阶,等.人乳头瘤病毒18 E6、E7和TPA协同诱发人胚食管上皮细胞恶性转化的研究[J].病毒学报1999,15(1)：1-5.
[25]Vinokurova S, Wentzensen N, Kraus I, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions [J]. Cancer Res 2008,68(1): 307-313.
[26]Zhou XB, Xu NZ. Current advances in the mechanic studies of human papillomavirus induced oncogenesis [J]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2007,29(5):673-677.
[27]De Lange T. Shelterin:the protein complex that shapes and safeguards human telomeres [J]. Genes Dev 2005,19 (18):2100-2110
[28]Flores I, Cayuela ML, Blasco MA. Effects of telomerase and telomere length on epidermal stem cell behavior [J]. Science 2005,309 (5738):125321256
[29]Kim M K, Kang MR, Nam HW, et al. Regulation of telomeric repeat binding factor 1 binding to telomeres by casein kinase 22 mediated phosphorylation [J]. J Biol Chem 2008,283(20):14144-52.
[30]Loayza D, de Lange T. POT1 as a terminal transducer of TRF1 telomere length control [J]. Nature,2003,423 (6943):1013-1018.
[31]Bailey SM. Telomeres and double-strand breaks 2 all's well that "ends" well [J]. Radiat Res 2008,169 (1):127.
[32]van Overbeek M, de Lange T. Apollo, an artemis-related nuclease, interacts with TRF2 and protects human telomeres in S Phase [J]. Curr Biol 2006,16 (13):1295-1302.
[33]Gonzalo S, Jaco I, Fraga MF, et al. DNA methyltransferases control telomere length and telomere recombination in mammalian cells [J]. Nat Cell Biol 2006, 8(4):416-424.
[34]Ottaviani A, Gilson E, Magdinier F. Telomeric position effect:From the yeast paradigm to human pathologies [J]. Biochimie 2008,90(1):932107.
[35]Arias-Pulido H, Peyton CL, Joste NE, Vargas H, Wheeler CM. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer [J]. J Clin Microbiol 2006,44(5):1755-1762.
[36]Guo M, Sneige N, Silva EG, Jan YJ, Cogdell DE, Lin E, Luthra R, Zhang W: Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma [J]. Modern Pathology 2007,20(2):256-266.
[37]Cawthon RM. Telomere measurement by quantitative PCR [J]. Nucleic Acids Res 2002; 30(10):e47.
[38]Dong W, Wang L, Chen X, Sun P, Wu Y. Upregulation and CpG island hypomethylation of the TRF2 gene in human gastric cancer [J]. Dig Dis Sci 2010, 55(4):997-1003.
[39]Oh BK, Urn TH, Choi GH, Park YN. Frequent changes in subtelomeric DNA methylation patterns and its relevance to telomere regulation during human hepatocarcinogenesis [J]. Int J Cancer 2011,128(4):857-68.
[40]Lee ME, Rha SY, Jeung HC, Chung HC, Oh BK. Subtelomeric DNA methylation and telomere length in human cancer cells [J]. Cancer Lett 2009,281(1):82-91.
[41]Jiang J, Zhao LJ, Zhao C, Zhang G, Zhao Y, Li JR, et al. Hypomethylated CpG around the transcription start site enables TERT expression and HPV 16 E6 regulates TERT methylation in cervical cancer cells [J]. Gynecol Oncol 2012, 124(3):534-41.
[42]吕丽春,沈忠英,邱向南,唐纯志,沈健,蔡唯佳.高低发区食管癌组织人乳头状瘤病毒的PCR检测[J].癌症1997,16(5)：341-342.
[43]Feng S, Zheng J, Du X, Tan Y, Yang H, Zhang H, Zhang Z. Human papillomavirus was not detected by PCR using multiple consensus primer sets in esophageal adenocarcinomas in Chinese patients [J]. J Med Virol 2013, 85(6):1053-7.
[44]Liu HY, Zhou SL, Ku JW, Zhang DY, Li B, et al. Prevalence of human papillomavirus infection in esophageal and cervical cancers in the high incidence area for the two diseases from 2007 to 2009 in Linzhou of Henan Province, Northern China [J]. Arch Virol.2014 Jan 3. [Epub ahead of print]
[45]Li X, Gao C, Yang Y, et al. Systematic review with meta-analysis:the association between human papillomavirus infection and oesophageal cancer [J]. Aliment Pharmacol Ther 2014,39(3):270-81
[46]Antunes LC, Prolla JC, de Barros Lopes A, et al. No evidence of HPV DNA in esophageal squamous cell carcinoma in a population of Southern Brazil [J]. World J Gastroenterol 2013,19(39):6598-603.
[47]Yong F, Xudong N, Lijie T. Human papillomavirus types 16 and 18 in esophagus squamous cell carcinoma:a meta-analysis [J]. Ann Epidemiol 2013, 23(11):726-34
[48]Liyanage SS, Rahman B, Ridda I, et al. The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma:a meta-analysis [J]. PLoS One 2013,24;8(7):e69238
[49]Haeri H, Mardany O, Asadi-Amoli F, Shahsiah R. Human papilloma virus and esophageal squamous cell carcinoma [J]. Acta Med Iran 2013,51(4):242-5.
[50]Feng S, Zheng J, Du X, et al. Human papillomavirus was not detected by PCR using multiple consensus primer sets in esophageal adenocarcinomas in Chinese patients [J]. J Med Virol 2013,85(6):1053-7.
[51]Williams VM, Filippova M, Filippov V, et al. HPV16 E6* induces oxidative stress and DNA damage [J]. J Virol 2014 Apr 2. [Epub ahead of print]
[52]Vega-Pena A, Illades-Aguiar B, Flores-Alfaro E, et al. Risk of progression of early cervical lesions is associated with integration and persistence of HPV-16 and expression of E6, Ki-67, and telomerase [J]. J Cytol 2013,30(4):226-32.
[53]Pretet JL, Charlot JF, Mougin C. Virological and carcinogenic aspects of HPV [J]. Bull Acad Natl Med 2007,191(3):611-23;
[54]Hamid NA, Brown C, Gaston K. The regulation of cell proliferation by the papillomavirus early proteins [J]. Cell Mol Life Sci 2009,66(10):1700-17.
[55]Kahla S, Kochbati L, Maalej M, et al. Situation of HPV 16 E2 Gene Status During Radiotherapy Treatment of Cervical Carcinoma [J]. Asian Pac J Cancer Prev 2014,15(6):2869-73.
[56]Badaracco G, Venuti A, Sedati A, et al. HPV-16 and HPV-18 in genital tumors: significantly different levels of viral integration and correlation to tumor invasiveness [J]. J Med Virol 2002,67(4):574-582
[57]Das BC, Sharma JK, Gopalakrishna V, et al. Analysis by polymerase chain reaction of the physical state of human papillomavirus type 16 DNA in cervical preneoplastic and neoplastic lesions [J]. Gen Virol 1992,73(Pt9):2327-2336
[58]Zhang LD, Zhang HM, et al. Investigation on HPV viral load and high risk HPV types infection among patients with infertility [J]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2007,21(2):159-161.
[59]牛永东,李恩民,吴贤英,郑瑞明,沈忠英,许丽艳.食管鳞癌中HPV-16/-18感染c-erb B-2、p53和Rb表达及其意义[J].肿瘤防治杂志2002,9(2)：138-141.
[60]Feng WJ, Danielle WL, Martin RJ, et al. Quantitation of Human papillomavirus 16 E6 and E7 Thin-Prep Papanicolaou Tests Using Real-Time Polymerase Chain Reaction Analysis [J]. Cancer 2002,94(15):2199-2209.
[61]Thorland EC, Myers SL, Persing DH, et al. Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites [J]. Cancer Res 2000,60(21):5916-5921.
[62]Klimov E, Vinokourova S, Moisjak E, et al. Human papillomaviruses and cervical tumors:mapping of integration sites and analysis of adjacent cellular sequences [J]. BMC Cancer 2002,13(2):24.
[63]Shay JW. Molecular pathogenesis of aging and cancer:are telomeres and telomerase the connection [J]. J Clin Pathol 1997,50(10):799-800.
[64]Hsu CP, Lee LW, Shai SE, Chen CY. Clinical significance of telomerase and its associate genes expression in the maintenance of telomere length in squamous cell carcinoma of the esophagus [J]. World J Gastroenterol 2005, 11(44):6941-7.
[65]Queisser A, Heeg S, Thaler M, von Werder A. Inhibition of telomerase induces alternative lengthening of telomeres during humanesophageal carcinogenesis [J]. Cancer Genet 2013,206(11):374-86
[66]Lin SW, Abnet CC, Freedman ND, et al. Measuring telomere length for the early detection of precursor lesions of esophageal squamous cell carcinoma [J]. BMC Cancer 2013,5;13:578.
[67]Pal J, Gold JS, Munshi NC, Shammas MA. Biology of telomeres:importance in etiology of esophageal cancer and as therapeutic target [J]. Transl Res 2013, 162(6):364-70.
[68]Cesare AJ, Reddel RR. Telomere uncapping and alternative lengthening of telomeres [J]. Mech Ageing Dev 2008,129(1):99-108.
[69]Tatsumoto N, Hiyama E, Murakami Y, et al. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer [J]. Clin Cancer Res 2000,6(7):2696-701.
[70]Lu L, Zhang C, Zhu G, et al. Telomerase expression and telomere length in breast cancer and their associations withadjuvant treatment and disease outcome [J]. Breast Cancer Research 2011,13(3):R56.
[71]Oh BK1, Kim H, Park YN, et al. High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis [J]. Laboratory Investigation 2008,88(2):144-152.
[72]Shen ZY, Xu LY, Li EM, et al. The multistage process of carcinogenesis in human esophageal epithelial cells induced by human papillomavirus [J]. Oncol Rep 2004,11(3):647-54.
[73]Shen ZY, Xu LY, Li C, Cai WJ, Shen J, Chen JY, et al.. A comparative study of telomerase activity and malignant phenotype in multistage carcinogenesis of esophageal epithelial cells induced by human papillomavirus [J]. Int J Mol Med 2001,8(6):633-9.
[74]郭艳合,张义玲,刘立,等.哺乳动物细胞衰老调节的新机制——端粒的表观遗传修饰[J].中国生物化学与分子生物学报2008,24(10)：895-901.
[75]李伟,陶凯雄hTERT表达的表观遗传调控研究进展[J].世界华人消化杂志2010,18(10)：1026-1031.
[76]Marciniak R A, Cavazos D, Montellano R, et al. A novel telomere structure in a human alternative lengthening of telomeres cell line [J]. Cancer Res 2005,65 (7):2730-2737.
[77]Okano M, Bell DW, Haber DA, et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development [J]. Cell 1999,99 (3):247-257.
[78]Gonzalo S, Jaco I, Fraga MF, et al. DNA methyltransferases control telomere length and telomere recombination in mammalian cells [J]. Nat Cell Biol 2006,8 (4):416-424.
[79]Kong CM, Lee XW, Wang X. Telomere shortening in human diseases [J]. FEBS J 2013,280(14):3180-93.
[80]Pal J, Gold JS, Munshi NC, Shammas MA. Biology of telomeres:importance in etiology of esophageal cancer and as therapeutic target [J]. Transl Res 2013, 162(6):364-70
[81]Gunes C, Rudolph KL. The role of telomeres in stem cells and cancer [J]. Cell 2013,152(3):390-3.
[1]Grieder C, Blackburn E. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts [J]. Cell,1985,43 (2 Pt 1):405-13.
[2]Vogel G, Pennisi E. Physiology Nobel. U.S. Researchers recognized for work on telomeres. Science,2009; 326 (5950):212-213.
[3]Harrington L. Those dam-aged telomeres! [J]. Curr Opin Genet Dev,2004,14 (1):22-8
[4]Shin JS, Hong A, Solomon MJ, et al. The role of telomeres andtelomerase in the pathology of human cancer and aging [J]. Pathology,2006,38(2):103-113.
[5]Djojosubroto MW, Choi YS, Lee HW, et al. Telomeres and telomerase in aging, regeneration and cancer [J]. Mol Cells,2003,15 (2):164-175.
[6]Gilley D, Tanaka H, et al. Telomere dysfunction in aging and cancer [J]. The International Journal of Biochemistry CellBiology,2005,37(5):1000-1013.
[7]Marusic L, AntonM, Tidy A, et al. Reprogramming of telomerase by expression of mutant telomerase RN A template in human cells leads to altered telomeres that correlate with reducde cell viability [J]. Mol Cell Biol,1997,17(11):6394-6401.
[8]Mergny JL, Riou JF, Mailliet P, et al. Natural and pharmacological regulation of telomerase [J]. Nucleic Acids Res,2002,30(4):839-865.
[9]Blasco MA. Telomeres and human disease:ageing, cancer and beyond [J]. Nature Review,2005,6 (8):611-622.
[10]De Lange T. Shelterin:the protein complex that shapes and safeguards human telomeres [J]. Genes Dev,2005,19 (18):2100-2110.
[11]Hsiao SJ, Smith S. Tankyrase function at telomeres, spindle poles, and beyond [J]. Biochimie,2008,90(1):83-92.
[12]Kim MK, Kang MR, Nam HW, et al. Regulation of telomeric repeat binding factor 1 binding to telomeres by casein kinase 22 mediated phosphorylation [J]. J Biol Chem,2008,283(20):14144-52.
[13]Loayza D, de Lange T. POT1 as a terminal transducer of TRF1 telomere length control [J]. Nature,2003,423(6943):1013-1018.
[14]Bailey SM. Telomeres and double strand breaks 2 alls well that "ends" well [J]. Radiat Res,2008,169(1):127.
[15]van Overbeek M, de Lange T. Apollo an artemis related nuclease, interacts with TRF2 and protects human telomeres in S Phase [J]. Curr Biol,2006,16 (13): 1295-1302.
[16]Dimitrova N, de Lange T. MDC1 accelerates nonhomologous end joining of dysfunctional telomeres [J]. Genes Dev,2006,20(23):3238-3243.
[17]Denchi EL, de Lange T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1 [J]. Nature,2007,448 (7157):1068-1071.
[18]Karlseder J. Telomere repeat binding factors:keeping the ends in check [J]. Cancer Lett,2003,194(2):189-197.
[19]Ohki R, Ishikawa F. Telomere-bound TRF1 and TRF2 stall the replication fork at telomeric repeats [J]. Nucleic Acids Res,2004,32 (5):1627-1637.
[20]Karlseder J, Broccoli D, Dai Y, et al. p53-and ATM-dependent apoptosis induced by telomeres lacking TRF2 [J]. Science,1999,283 (5406):1321-1325.
[21]Gomez M, Wu J, Schreiber V, et al. PARP1 Is a TRF2-associated poly (ADP-ribose) polymerase and protects eroded telomeres [J]. Mol Biol Cell,2006, 17(4):1686-1696.
[22]Feng J, Funk W D, Wang S S, et al. The RNA component of human telomerase [J]. Science,1995,269(5228):1236-1241.
[22]Ren X, Gavory G, Li H, et al. Identification of a new RNA.RNA interaction site for human telomerase RNA (hTR):structuralimplications for hTR accumulation and a dyskeratosis congenital point mutation [J]. Nucleic Acids Res,2003,31(22): 6509-6515.
[24]Chen JL, Greider CW. Template boundary definition in mammalian telomerase [J]. Genes Dev,2003(22),17:2747-2752.
[25]Tzfati Y, Fulton TB, Roy J, et al. Template boundary in a yeast telomerase specified by RNA structure [J]. Science,2000,288(5467):863-867.
[26]Uchida N, Otsuka T, Shigematsu H, et al. Differential gene expression of human telomerase-associated protein hTERT andTEP1 in human hematopoietic cells [J]. Leuk Res,1999,23(12):1127-1132.
[27]Kickhoefer VA, Liu Y, Kong L B, et al. The Telomerase/vault-associated protein TEP1 is required for vault RNA stability and its association with the vault particle [J]. J Cell Biol,2001,152(1):157-164.
[28]Theimer CA, Feigon J. Structure and function of telomerase RNA [J]. Curr Opin Struct Biol,2006,16(3):307-318.
[29]Autexier C, Lue NF. The structure and function of telomerase reverse transcriptase [J]. Annu Rev Biochem,2006,75:493-517.
[30]Chang JT, Chen YL, Yang HT, et al. Differential regulation of telomerase activity by six telomerase subunits [J]. Eur J Biochem,2002,269(14):3442-3450.
[31]Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells [J]. Cell,2003,114(2):241-253.
[32]Okuda K, Bardeguez A, Gardner JP, et al. Telomere length in the newborn [J]. Pediatric Research,2002,52(3):377-381.
[33]Butler MG, Tilburt J, DeVries A, et al. Comparison of chromosometelomere integrity inmultiple tissues from subjects at different ages [J]. Cancer Genetics and Cytogenetics,1998,105(2):138-144.
[34]Benetos A, Okuda K, Lajemi M, et al. Telomere length as an indicator of biological aging:the gender effect and relation with pulse pressure andpulse wave velocity [J]. Hypertension,2011,37(2):381-385.
[35]Misiti S, Nanni S, Fontemaggi G, et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells [J]. Molecular and Cellular Biology,2000,20(11):3764-3771.
[36]陈宇,张伟丽,惠汝太.染色体端粒损耗与心血管病及血管危险因子的关系[J].中国分子心脏病学杂志,2009(4)：246-249.
[37]Bekaert S, De Meyer T, Rietzsehel ER, et al. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease [J]. Aging Cell,2007,6(5):639-647.
[38]Zglinicki TV. Oxidative stress shortens telomeres [J]. Trends in Biochemical science,2002,27(7):339-344.
[39]Matthews C, Gorenne I, Scott S, et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis:effects of telomerase and oxidative stress [J]. Circulation Research,2006,99(2):156-164.
[40]Haendeler J, Hoffmann J, Diehl JF, et al. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells [J]. Circulation Research,2006,94(6):768-775.
[41]Nawrot TS, Staessen JA, Holvoet P, et al. Telomere length and its associations with oxidized-LDL, carotid artery distensibility and smoking [J]. Front. Bioscience,2010,2:1164-1168.
[42]Xu D, Erickson S, Szeps M, et al. Interferon a down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells [J]. Blood,2000,96(13):4313-4318.
[43]Aisner DL, Wright WE, Shay JW. Telomerase regulation:not just flipping the switch [J]. Curr Opin Genet Dev,2002(1),12:80-85.
[44]Collins K, Mitchell JR. Telomerase in the human organism [J]. Oncogene,2002, 21(4):564-579.
[45]Blasco MA. Mammalian telomeres and telomerase:why they matter for cancer and aging [J]. Eur J Cell Biol,2003,82(9):441-446.
[46]Shay JW, Bacchetti S. A survey of telomerase activity in human cancer [J]. Eur J Cancer,1997,33(5):787-791.
[47]Cerone MA, Londono-Vallejo JA, Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells [J]. Hum Mol Genet, 2001,10(18):1945-1952.
[48]Bailey SM, Brenneman MA, Goodwin EH. Frequent recombination in telomeric DNA may extend the proliferative life of telomerase-negative cells [J]. Nucleic Acids Res,2004,32(12):3743-3751.
[49]de The H, Lavau C, Marchio A, et al. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR [J]. Cell,1991,66(4):675-684.
[50]Londono-Vallejo JA, Der-Sarkissian H, Cazes L, et al. Alternative lengthening of telomeres is characterized by high rates of telomeric exchange [J]. Cancer Res, 2004,64(7):2324-2327.
[50]Mason JM, Konev AY, Biessmann H. Telomeric position effect in 55'drosophila melanogaster reflects a telomere length control mechanism [J]. Genetica,2003, 117(2-3):319-325.
[51]巩燕,房殿春.端粒位置效应与人类衰老[J].细胞生物学杂志,2004,26：513-515.
[52]Baur JA, Zou Y, Shay JW, et al. Telomereposition effect in human cells [J]. Science,2001,292(5524):2075-2077.
[53]Karlseder J, Smogorzewska A, de Lange W, et al. Senescence induced by altered telomere state, not telomere loss [J]. Science,2002,295(5564):2446-2449.
[54]Ottaviani AGilson E, Magdinier E. Telomeric position effect:from the yeast paradigm to human pathologies?[J]. Biochimie,2008,90(1):93-107.
[55]Doheny JG, Mottus R, Grigliatti TA. Telomeric position effect a third silencing mechanism in eukaryotes [J]. PLoS ONE,2008,3(12):3864.
[56]Bilaud T, Brun C, Ancelin K, et al. Telomeric localization of TRF2, anovel human telobox protein [J]. Nat Genet,1997,17(2):236-239.
[57]Donigian JR, de Lange T. The role of the poly (ADP-ribose) polymerase tankyrasel in telomere Length control by the TRF1 component of the sheherin complex [J]. J Biol Chem,2007,282(31):22662-22667.
[58]Kim H, Lee O H, Xin H, et al. TRF2 functions as aprotein hub and regulates telomere maintenance by recognizing specific peptide motifs [J]. Nat Struct Mol Biol,2009,16(4):372-379.
[59]Chiang YJ, Kim S H, Tessarollo L, et al. Telomere-associated protein TIN2 is essential for early embryonic development through a telomerase-independent pathway [J]. Mol Cell Biol,2004,24(15):6631-6634.
[60]Sfeir A, Kabir S, vall Overbeek M, et al. Loss of Rapl induces telomere recombination in the absence of NHEJ or a DNA damage signal [J]. Science, 2010,327 (5973):1657-1661.
[61]Tejera AM, Stagno DM, Thanasoula M, et al. TPP1 is required for TERT recruitment, telomere elongation during nuclear reprogramming, and normal skin development in mice [J]. Dev Cell,2010,18(5):775-789.
[62]Wu L, Muhani AS, He H, et al. PotI deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres [J]. Cell,2006,126(1):49-62.
[63]Marciniak RA, Cavazos D, Montellano R, et al. A novel telomere structure in a human alternative lengthening of telomeres cell line [J]. Cancer Res,2005,65 (7): 2730-2737.
[64]Okano M, Bell DW, Haber DA, et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development [J]. Cell,1999,99 (3):247-257.
[65]Gonzalo S, Jaco I, Fraga MF, et al. DNA methyltransferases control telomere length and telomere recombination in mammalian cells [J]. Nat Cell Biol,2006, 8(4):416-424.
[67]Gonzalo S, Garcia-Cao M, Fraga MF, et al. Role of the RBI familyin stabilizing histone methylation at constitutive heterochromatin [J]. Nat Cell Biol,2005,7 (4): 420-428
[68]Benetti M, Garcia-Cao M, Blasco MA. Telomere length regulatesthe epigenetic status of mammalian telomeres and subtelomeres [J]. Nat Genet,2007,39 (2): 243-250.
[69]Venturini L, Daidone MG, Motta R, et al. Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors:expression and prognostic relevance [J]. Neuro-Oncology,2012,14(6):736-744.
[70]Saini N, Srinivasan R, Chawla Y. Et al. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status [J]. Liver International,2009,29(8):1162-70.
[71]PM Lansdorp NP, Verwoerd FM, Van de Pijike, et al. Heterogeneity in telomere length of hmnan chromosomes [J]. Hum. Mol. Genet.1996,5(5):685-91.
[72]McNeil N, Ried T. Novel molecular cytogenetic techniques for identifying complex chromosomal rearrangements:technology and applications in molecular medicine [J]. Expert Rev. Med,2000,2000:1-14.
[73]Baerlocher GM, Mak J, Tien T, et al. Telomere length messurment by fluorescence in situ hybridization and flow cytometry:tips and pitfalls [J]. Cytomcuy,2002,47(2):88-99.
[74]Gil ME, Coetzer TL. Real-time quantitative PCR of telomere length [J]. Molecular Biotechnology,2004,27(2):169-172.
[75]Lu LG, Zhang, Zhu GJ, et al. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome [J]. Breast Cancer Research,2011,13(3):R56
[76]Artandi SE, DePinho RA. Telomeres and telomerase in cancer [J]. Carcinogenesis,2010,31(1):9-18.
[77]Shin JS, Hong A, Solomon MJ, et al. The role of telomeres and telomerase in the pathology of human cancer and aging [J]. Pathology,2006,38(2):103-13.
[78]Giines C, Rudolph KL. The role of telomeres in stem cells and cancer [J]. Cell, 2013,152(3):390-3.
[79]Kong CM, Lee XW, Wang X. Telomere shortening in human diseases [J]. FEBS J, 2013,280(14):3180-93.
[80]Saleh S, Lam AK, Ho YH. Real -time PCR quantification of human telomerase reverse transcriptase (hTERT) in colorectal cancer [J]. Pathology,2008,40 (1):25-30.
[81]Rampazzo E, Bertorelle R, Serra L, Terrin L, Candiotto C, Pucciarelli S, et al. Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers [J]. Br J Cancer,2010,102(8):1300-5.
[81]Abbott A. Chromosome protection scoops Nobel [J]. Nature,2009,461(7265): 706-707.
[82]Tatsumoto N, Hiyama E, Murakami Y, et al. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer [J]. Clin Cancer Res,2000,6(7):2696-701.
[83]Lu L, Zhang C, Zhu G, et al. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome [J]. Breast Cancer Research,2011,13(3):R56.
[84]Oh BK, Kim H, Park YN, et al. High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis [J]. Laboratory Investigation,2008,88(2):144-152.
[85]Pal J, Gold JS, Munshi NC, Shammas MA. Biology of telomeres:importance in etiology of esophageal cancer and as therapeutic target [J]. Transl Res,2013, 162(6):364-370.
[86]Risques RA, Vaughan TL, Li X, et al. Leukocyte telomere length predicts cancer risk in Barrett's esophagus [J]. Cancer Epidemiol Biomarkers Prev,2007,16 (12): 2649-2655.
[87]Xing J, Ajani JA, Chen M, et al. Constitutive short telomere length of chromosome 17p and 12q but not llq and 2p is associated with an increased risk for esophageal cancer [J]. Cancer Prev Res (Phila),2009,2 (5):459-465.
[88]Feng S, Zheng J, Du X, et al. Human papillomavirus was not detected by PCR using multiple consensus primer sets in esophageal adenocarcinomas in Chinese patients [J]. J Med Virol,2013,85(6):1053-1057.
[89]Liu HY, Zhou SL, Ku JW, et al. Prevalence of human papillomavirus infection in esophageal and cervical cancers in the high incidence area for the two diseases from 2007 to 2009 in Linzhou of Henan Province, Northern China [J]. Arch Virol. 2014 Jan 3. [Epub ahead of print].
[90]Li X, Gao C, Yang Y, et al. Systematic review with meta-analysis:the association between human papillomavirus infection and oesophageal cancer [J]. Aliment Pharmacol Ther,2014,39(3):270-81
[91]Antunes LC, Prolla JC, de Barros Lopes A, et al. No evidence of HPV DNA in esophageal squamous cell carcinoma in a population of Southern Brazil [J]. World J Gastroenterol,2013,19(39):6598-603.
[92]Zhang H, Jin Y, Chen X, et al. Papillomavirus type 16 E6/E7 and human telomerase reverse transcriptase in esophageal cell immortalization and early transformation [J]. Cancer Lett,2007,245(1-2):184-94.
[93]Hsu CP, Lee LW, Shai SE, et al. Clinical significance of telomerase and its associate genes expression in the maintenance of telomere length in squamous cell carcinoma of the esophagus [J]. World J Gastroenterol,2005,11(44):6941-6917.
[94]Liu X, Dakic A, Zhang Y, et al. HPV E6 protein interacts physically and functionally with the cellular telomerase complex [J]. Proc Natl Acad Sci USA, 2009,106(44):18780-18785.
[95]Pooley KA, Sandhu MS, Tyrer J, et al. Telomere length in prospective and retrospective cancer case-control studies [J]. Cancer Res,2010,70 (8):3170-3176.
[96]Rampazzo E, Bertorelle R, Serra L, et al. Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers [J]. Br J Cancer,2010,102(8):1300-5.
[97]Frias C, Pampalona J, Genesca A, et al. Telomere dysfunction and genome instability [J]. Front Biosci,2012,17:2181-2196.
[98]Begus-Nahrmann Y, Hartmann D, Kraus J, et al. Transient telomere dysfunction induces chromosomal instability and promotes carcinogenesis [J]. J Clin Invest, 2012,122(6):2283-2288.
[99]Perera SA, Maser RS, Xia H, et al. Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer [J]. Carcinogenesis,2008,29 (4):747-753.
[100]Jones AM, Beggs AD, Carvajal-Carmona L, et al. TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres [J]. Gut,2012,61(2):248-254.
[101]Lan Q, Cawthon R, Shen M, et al. A prospective study of telomere length measured by monochrome multiplex quantitative PCR and risk of non-Hodgkin lymphoma [J]. Clin Cancer Res,2009,15(23):7429-7433.
[102]Artandi SE, DePinho RA. Telomeres and telomerase in cancer [J]. Carcinogenesis,2010,31(1):9-18.
[103]Cui Y, Cai Q, Qu S, et al. Association of leukocyte telomere length with colorectal cancer risk:Nested case-control findings from the Shanghai women's health study [J]. Cancer Epidemiol Biomarkers Prev,2012,21(10):1807-1813.
[104]Mu Y, Zhang Q, Mei L, et al. Telomere shortening occurs early during gastrocarcinogenesis [J]. Med Oncol,2012,29(2):893-898.
[105]Liu X, Bao G, Huo T, et al. Constitutive telomere length and gastric cancer risk: case-control analysis in Chinese Han population [J]. Cancer Sci,2009,100 (7): 1300-1305.
[106]Hou L, Savage SA, Blaser MJ, et al. Telomere length in peripheral leukocyte DNA and gastric cancer risk [J]. Cancer Epidemiol Biomarkers Prev,2009, 18(11):103-3109.
[107]Hu H, Zhang Y, Zou M, et al. Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is associated with telomere shortening and may contribute to multistage carcinogenesis of Gastric cancer [J]. J Cancer Res Clin Oneol,2010, 136(9):1407-1414.
[108]Wan SM, Tie J, Zhang YF, et al. Silencing of the hPOT1 gene by RNA inference promotes apoptosis and inhibits proliferation and aggressive phenotype of gastric cancer cells, likely through up-regulating PinXl expression [J]. J Clin Pathol, 2011,64(12):1051-1057.
[109]Gao J, Zhang J, Long Y, et al. Expression of telomere binding proteins in gastric cancer and correlation with clinicopathological parameters [J]. Asia Pac J Clin Oncol,2011,7(4):339-345.
[110]Yao DF, Wu W, Yao M, et al. Dynamic alteration of telomerase expression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma [J]. World J Gastroenterol,2006,12(31):4966-4972.
[111]Oh BK, Kim YJ, Park C, et al. Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis [J]. Am J Pathol,2005,166(1):73-80.
[112]Oh BK, Kim H, Park YN, et al. High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis [J]. Lab Invest,2008, 88(2):144-52.
[113]Guo Y, Zhuo X, Liu E, et al. Difference in hTERT gene expressions between HBsAg-positive and HBsAg-negative hepatocellular carcinoma [J]. J Hua zhong Univ Sci Technolog Med Sci,2005,25(3):303-306.
[114]OH BK, Kim YJ, Park YN, et al. Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis [J]. Am J Gastroenterol,2006,101(4):831-838.
[115]Qu ZL, Zou SQ, Cui NQ, et al. Upregulation of human telomerase reverse transcriptase mRNA expression by in vitro transfection of hepatitis B virus X gene into human hepatocarcinoma and cholangiocarcinoma cells [J]. World J Gastroenterol,2005, 11(36):5627-5632.
[116]Skinner HG, Gangnon RE, Litzelman K, et al. Telomere length and pancreatic cancer:a case-control study [J]. Cancer Epidemiol Biomarkers Prev,2012,21 (11):2095-2100.
[117]Seimiya H, Muramatsu Y, Ohishi T, et al. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics [J]. Cancer Cell,2005,7(1):25-37.